SCHEMBL3968950

SCHEMBL3968950

CCc1nc2c(C[O])cccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDAH1 O94760 1/20 0.50
▸ CHEK1 O14757 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ GLA P06280 1/20 0.38
▸ TNKS2 Q9H2K2 1/20 0.38
▸ HTR6 P50406 2/20 0.37
▸ GAA P10253 2/20 0.37
▸ HTT P42858 1/20 0.37
▸ DAO P14920 2/20 0.36
▸ DDO Q99489 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ ATP4A P20648 1/20 0.35
▸ ATP4B P51164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2899660 0.91 DDAH1 (0.55) DDAH1CHEK1ADORA3ADORA2AADORA1
SCHEMBL3973661 0.83 GRIN2B (0.36) CHEK1HTR6GAAHTTSMN1; SMN2
SCHEMBL6681270 0.80 CHEK1 (0.45) DDAH1CHEK1ALDH1A1HTR6DAO
SCHEMBL6582523 0.80 DDAH1 (0.42) DDAH1CHEK1ALDH1A1HTR6HTT
SCHEMBL4191637 0.79 PARP1 (0.53) ALDH1A1HTTSMN1; SMN2KDM4EATP4A
SCHEMBL4919548 0.77 DDAH1 (0.55) DDAH1ALDH1A1GAA
SCHEMBL30518181 0.77 DDAH1 (0.55) DDAH1ALDH1A1GAA
SCHEMBL8169941 0.76 POLB (0.46) —
SCHEMBL1918622 0.76 DDAH1 (0.53) DDAH1CHEK1ADORA3ADORA2AADORA1
SCHEMBL10072578 0.76 GRIN1 (0.54) DDAH1CHEK1ADORA3ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 — — US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 — — US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 — — US disclosed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 DDAH1 710/4885CHEK1 4379/4885ADORA3 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback